Daiichi Sankyo co-developed datopotamab deruxtecan with partners, and Jim Cramer compared AstraZeneca to Novartis.

The entities involved

• Daiichi Sankyo →

  Japanese pharmaceutical company

  • A dispute over mandatory tender offer approvals has arisen, leading to NCLT approval for the amalgamation of a subsidiary involving several companies.Sun 09:52
  • The Supreme Court disposed of the petition concerning the legal dispute between Fortis Healthcare and Daiichi Sankyo.Sun 09:52
• AstraZeneca →

  British-Swedish pharmaceutical company

  • AstraZeneca's trial failure has created a competitive advantage for Alnylam Pharmaceuticals, which is leveraging AI in its commercial execution.Mon 11:04
  • Pharmaceutical companies are adopting AI for clinical data gathering, product promotion, and prototyping.Sat 18:52
• Novartis →

  Swiss-American multinational pharmaceutical corporation

  • Novartis acquired Avidity in a $12 billion purchase, while Trump simultaneously threatened Swiss businesses with tariffs.Sat 01:46
  • GSK and Novartis are identified as major pharmaceutical companies.Fri 02:16